Clinical Trials Logo

Actinic Keratoses clinical trials

View clinical trials related to Actinic Keratoses.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05937529 Completed - Actinic Keratoses Clinical Trials

Impact of Madecassoside and 5 % Panthenol Cream in Post Photodynamic Therapy for Actinic Keratosis

Start date: September 27, 2023
Phase: N/A
Study type: Interventional

Premalignant AKs are highly frequent in the light-skinned populations with an increasing incidence. PDT is considered a well-establish treatment for these lesions, and therefore it is essential to achieve an optimal and effective treatment as possible. The present study proposes a new post-treatment modality with application of an anti-inflammatory moisturizer Cicaplast Baume B5+ to the treated areas that may improve the overall patient satisfaction and minimize the local skin reactions. Treatment regime consists of two daily applications of Cicaplast Baume B5+ for 14 days, and this regime is not associated with increased risk of systemic AEs or serious events.

NCT ID: NCT05725213 Completed - Actinic Keratoses Clinical Trials

ADL-PDT Under Routine Clinical Conditions in Patients With Actinic Keratosis

Start date: November 1, 2022
Phase:
Study type: Observational

The objective of this non-interventional study (NIS) is to gain comprehensive insights into the practicability of ADL-PDT with Metvix® in patients with actinic keratoses under real-world conditions.

NCT ID: NCT05522036 Completed - Actinic Keratoses Clinical Trials

Clinical Evaluation of a Short Illumination Duration (35 Minutes) When Performing PDT of AK Using the Dermaris ®

Dermaris-35
Start date: January 1, 2022
Phase: N/A
Study type: Interventional

This clinical study aims aims to evaluate the clinical outcomes of SDL-PDT (simulated daylight Photodynamic Therapy) using the Dermaris in patients treated for AK lesions of the scalp at our medical dermatology center using only 35 minutes low-intensity light exposure.

NCT ID: NCT05365386 Completed - Actinic Keratoses Clinical Trials

Efficacy and Safety of Tixel Treatment on Facial and/or Scalp Actinic Keratoses.

Start date: May 17, 2022
Phase: N/A
Study type: Interventional

Evaluation of the Efficacy and Safety of a thermal fractional skin treatment system (Tixel) for the treatment of facial and/or scalp actinic keratoses

NCT ID: NCT05078827 Completed - Actinic Keratoses Clinical Trials

Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis

Start date: March 1, 2022
Phase: Phase 3
Study type: Interventional

Fluorouracil is recommended for the topical treatment of multiple actinic or solar keratoses. In the 5% strength, it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites.

NCT ID: NCT04969419 Completed - Melanoma (Skin) Clinical Trials

Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo

Start date: June 18, 2021
Phase:
Study type: Observational

This study examines melanoma and nonmelanoma skin cancer in people diagnosed with vitiligo compared to matched controls.

NCT ID: NCT04875026 Completed - Actinic Keratoses Clinical Trials

Frequency and Intensity of Local Reactions in Patients Treated With 4% 5-FU vs 4% 5-FU Associated With an Emollient Cream: a Randomised, Controlled Clinical Trial

Start date: February 16, 2021
Phase: Phase 4
Study type: Interventional

Transient local skin reactions with topical Actinic Keratosis treatments such as 5-FluoroUracil (5-FU) often lead to non-adhesion from patients and thus to treatment failure. In regards to 5-FU treatment, these local reactions are related to the pharmacological action of the molecule. The current therapeutic challenge is to reduce the local reactions induced by 5-FU without interfering with its efficacy, in particular by the use of an emollient cream. The aim of the present study is to investigate how the use of an emollient, namely Dexeryl, could improve the local skin reactions occurring during 4 weeks of a 4% 5-FU treatment.

NCT ID: NCT04843553 Completed - Actinic Keratoses Clinical Trials

Nicotinamide for Prevention of Pre-malignant Actinic Keratosis in Kidney Transplant Recipients

NICE
Start date: October 14, 2016
Phase: Early Phase 1
Study type: Interventional

Skin cancers and pre-cancerous growths (called actinic keratoses, "AKs"), that aren't melanomas, develop in patients with a kidney transplant at excessive rates. When these pre-cancerous AKs, and "non-melanoma" skin cancers occur in kidney transplant patients, they tend to be aggressive, and require frequent medical procedures, often surgery, for the removal of the skin cancers. If not removed adequately the pre-cancers can develop into skin cancers, and the skin cancers, if not removed, may spread, and even cause death. Reducing the occurrence and complications of these skin cancers and pre-cancers in kidney transplant patients with a safe, effective, well-tolerated treatment taken by mouth would be an important medical advance. We are testing oral nicotinamide (NAM)-a B-vitamin compound-for that purpose. Approximately fifty kidney transplant patients who have had at least one non-melanoma skin cancer in the past, will be given randomized to receive NAM, 1 gram twice daily by mouth, or identical pills without NAM, and followed for 1 year to see if NAM treatment reduces the numbers of pre-cancerous AKs, and non-melanoma skin cancers they develop. Patients will be asked to come to the clinic for 3 follow up visits (every 4 months for up to 12 months). They will receive a full body skin exam by a dermatologist, have detailed counting of AKs and biopsies for any suspicious lesions as standard of care. Blood will also be drawn as well as a urine sample obtained at each visit for safety assessment and storage. We will also ask them to answer a series of questions about dietary patterns and intake of whole foods and supplements.

NCT ID: NCT04842422 Completed - Actinic Keratoses Clinical Trials

Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream

Start date: April 16, 2021
Phase: Phase 4
Study type: Interventional

Earliest Stage Treatment of Actinic Keratosis with Imiquimod 3.75% Cream: The study is to demonstrate that Aktinic Keratosis are present before they are clinically visible, i.e. in a subclinical stage. Since on the basis of the research situation, also subclinical AK can proliferate into the dermis, it is possible that with the application of Imiquimod on chronically light-exposed skin, undetected squamous cell carcinoma can be recognized and treated at the same time.

NCT ID: NCT04527653 Completed - Actinic Keratoses Clinical Trials

Evaluation of The Efficacy and Safety of Tixel Treatment for the Treatment of Facial and/or Scalp Actinic Keratoses

Start date: May 14, 2020
Phase: N/A
Study type: Interventional

Evaluation of the Efficacy and Safety of a thermal fractional skin treatment system (Tixel) for the treatment of facial and/or scalp actinic keratoses